CDKN2A and meningioma: As we have not identified any TERT promoter mutation or homozygous CDKN2A/B deletion in the full intermediate risk group meningiomas (62 cases, data not shown), we share the view of Hielscher and colleagues and do not recommend routine testing for TERT promoter mutations or dedicated assessment of homozygous CDKN2A/B deletions, the latter especially in the absence of methylation analysis [21].